Top entities: Immutep, Pomerantz LLP.

What category does this event fall under?

Business — classified as class action.

What is the market impact?

Direct. The market was significantly impacted by the 82.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Pomerantz LLP filed class action Immutep · Immutep issued press release

Is this event still developing?

This is an active story, last updated May 12, 2026. Coverage continues to evolve.

Business class action

Immutep Class Action Lawsuit Filed

Q: When did this event occur?

First reported May 07, 2026; last updated May 12, 2026.

Analysis based on 15 articles · First reported May 07, 2026 · Last updated May 12, 2026

Sentiment

-70

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market was significantly impacted by the 82.44% drop in Immutep's ADR price following the discontinuation of its Phase III study. This event highlights the risks associated with clinical trials in the biotechnology sector and can lead to increased scrutiny of similar companies. The class action lawsuit filed by Pomerantz LLP further adds to the negative sentiment surrounding Immutep.

Biotechnology Legal Services

Event Summary

A class action lawsuit has been filed against Immutep by Pomerantz LLP on behalf of investors. The lawsuit alleges securities fraud and other unlawful business practices by Immutep and its officers/directors. This follows Immutep's announcement on March 13, 2026, that the Independent Data Monitoring Committee recommended the discontinuation of its TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer due to futility. This news caused Immutep's American Depositary Receipt (ADR) price to plummet by 82.44%, closing at $0.48 per ADR. Investors have until July 6, 2026, to seek appointment as Lead Plaintiff in the class action.

Key Actions

100 Pomerantz LLP filed class action Immutep

90 Immutep issued press release

Entities Involved

stock

Immutep

Immutep is facing a class action lawsuit due to alleged securities fraud following the discontinuation of its TACTI-004 Phase III study, which caused its ADR price to fall significantly.

Importance 100 Sentiment -90

priv

Pomerantz LLP

Pomerantz LLP filed the class action lawsuit against Immutep on behalf of investors, seeking to recover damages for alleged securities fraud.

Importance 80 Sentiment 50

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard